{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:32:32Z","timestamp":1775273552380,"version":"3.50.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Hidradenitis Suppurativa (HS) is a major public health challenge affecting people globally, which is painful and the hard lumps under the skin are prone to infection. We aimed to investigate whether tofacitinib can help people with HS in a safe and effective way. In this study, we report two cases diagnosed with HS. Tofacitinib was used as a part of the treatment plan. The first patient received 5\u00a0mg of tofacitinib twice daily, 36\u00a0weeks, and the second one for 24\u00a0weeks. Clinical outcomes are described. The efficacy of tofacitinib in HS was confirmed in our study. The clinical characteristics of the patients improved after receiving tofacitinib. Lesions discharge significantly reduced, particularly in the axillary area. Tofacitinib may be useful as an adjuvant therapy when used in combination with other treatments. Further research in this area is required to improve our understanding of treatment with tofacitinib at HS.<\/jats:p>","DOI":"10.1093\/omcr\/omad003","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:15:23Z","timestamp":1679922923000},"source":"Crossref","is-referenced-by-count":12,"title":["Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature"],"prefix":"10.1093","volume":"2023","author":[{"given":"Afsaneh","family":"Sadeghzadeh Bazargan","sequence":"first","affiliation":[{"name":"Iran University of Medical Sciences Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, , Tehran 6715847141, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezoo","family":"Pashaei","sequence":"additional","affiliation":[{"name":"Iran University of Medical Sciences Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, , Tehran 6715847141, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[{"name":"Iran University of Medical Sciences Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, , Tehran 6715847141, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"key":"2023032713151240400_","first-page":"1168","article-title":"News into the pathogenesis of HS and therapeutical approaches","volume":"9","author":"Rosi","year":"2021","journal-title":"Biomedicine"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2229-5178.105454","article-title":"Acne inversa (Hidradenitis Suppurativa): a review with a focus on pathogenesis and treatment","volume":"4","author":"Wollina","year":"2013","journal-title":"Indian Dermatol Online J"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis Suppurativa: from pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2023032713151240400_","first-page":"1547","article-title":"Hidradenitis Suppurativa: a treatment challenge","volume":"72","author":"Shah","year":"2005","journal-title":"Am Fam Physician"},{"key":"2023032713151240400_","first-page":"239","article-title":"The role of androgens and estrogens in Hidradenitis Suppurativa\u2014a systematic review","volume":"24","author":"Riis","year":"2016","journal-title":"Acta Dermatovenerologica Croat"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7150\/ijms.7.240","article-title":"Surgical Management of Hidradenitis Suppurativa","volume":"7","author":"Menderes","year":"2010","journal-title":"Int J Med Sci"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/BS.S98177","article-title":"Adalimumab: a review of the reference product and biosimilars","volume":"6","author":"Azevedo","year":"2016","journal-title":"Biosimilars"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mayocpiqo.2021.03.007","article-title":"Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort","volume":"5","author":"Hayek","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jaad.2015.07.053","article-title":"Treatment of Hidradenitis Suppurativa with biologic medications","volume":"73","author":"Lee","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000462979","article-title":"Medical and surgical treatment of Hidradenitis Suppurativa: a review","volume":"3","author":"Scuderi","year":"2017","journal-title":"Ski Appendage Disord"},{"key":"2023032713151240400_","first-page":"1","article-title":"New perspectives on the treatment of Hidradenitis Suppurativa","volume":"12","author":"Amat-Samaranch","year":"2021","journal-title":"Ther Adv Chron Dis"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000513938","article-title":"Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient","volume":"13","author":"Berbert Ferreira","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"2023032713151240400_","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant Hidradenitis Suppurativa patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2023\/3\/omad003\/49630866\/omad003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2023\/3\/omad003\/49630866\/omad003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T18:30:26Z","timestamp":1702146626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omad003\/7085893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omad003","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2023,3,1]]},"article-number":"omad003"}}